It's a fundamental principle of human nature: The pain of loss is stronger than the pleasure of gain. So can the pain of potentially losing some cash motivate Americans to keep their commitments to exercise?
As we approach the cyclically sweet period between New Year's resolutions and swimsuit season, investors may think there are profitable opportunities in companies focused on diet and exercise. But you may be wise not to gorge on the stocks.
Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.
